Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Gemcitabine + PG545|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Gemcitabine||Gemzar||Difluorodeoxycytidine Hydrochlorothiazide|LY-188011||Chemotherapy - Antimetabolite 11||Gemzar (gemcitabine) is converted in cells to difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP), which act to inhibit ribonucleoside reductase and as a deoxynucleotide analog respectively, resulting in DNA strand termination and apoptosis (NCI Drug Dictionary).|
|PG545||Pixatimod||Pixatimod (PG545) is a heparan sulfate mimetic capable of inhibiting both heparanase and angiogenesis, which may result in tumor growth inhibition and anti-metastatic activity (PMID: 21285983, PMID: 32274726).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||pancreatic cancer||not applicable||Gemcitabine + PG545||Preclinical - Cell line xenograft||Actionable||In a preclinical study, human pancreatic cancer cells demonstrated increased apoptosis and tumor growth suppression both in culture and in cell line xenograft models when treated with a combination of PG545 and Gemzar (gemcitabine) (PMID: 25669977).||25669977|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|